DRDmitrii A. Reshetnikov

Dmitrii A. Reshetnikov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dmitrii A. Reshetnikov has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Inna Dolzhikova

    Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia

    3 shared publications
  • Alexander Gintsburg

    National Research Center for Epidemiology and Microbiology Named after the Honorary Academician N. F. Gamaleya, 18 Gamaleya St., 123098 Moscow, Russia

    2 shared publications
  • Andrei E. Siniavin

    Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named After Honorary Academician N. F. Gamaleya”, The Ministry of Health of the Russian Federation, Moscow 123089, Russia

    2 shared publications
  • Anna A. Iliukhina

    Federal State Budget Institution “National Research Centre for Epidemiology and Microbiology Named after Honorary Academician N F Gamaleya” of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia

    2 shared publications
  • Anna V. Kovyrshina

    National Research Center for Epidemiology and Microbiology Named After Honorary Academician N. F. Gamaleya, Ministry of Health, Moscow 123098, Russia

    2 shared publications
  • Boris S. Naroditsky

    The National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya of the Ministry of Health of the Russian Federation, 123098 Moscow, Russia

    2 shared publications

Latest Publications

  • Open Access

    A Lethal Pseudofilovirus Model in Ifnar1(-/-) Mice Using Recombinant Vesicular Stomatitis Viruses

    by Anna V. Mamatkulova, Inna V. Shuliakova, Olga V. Zubkova, Dmitrii A. Reshetnikov, Anna A. Iliukhina, Ilya D. Zorkov, Daria M. Grousova, Daria M. Savina, Olga Popova, Denis I. Zrelkin, et al.

    Filoviruses cause highly lethal infectious diseases with hemorrhagic symptoms and extremely high fatality rate (up to 90%). Although two vaccines against Ebola virus (EBOV) are licensed for application in endemic areas, vaccines against other filoviruses (SUDV, BDBV, MARV) are still at pre-clinical or clinical stages. The development of vaccines requires protective efficacy studies using animal models of infection. However, animal studies using wild-type filoviruses require maximum biosafety level (BSL-4), which hinders filoviral vaccine advancement. In this study, we developed a surrogate animal model of EBOV-, SUDV-, BDBV- and MARV- GP-mediated entry using Ifnar1-knockout (-/-) mice and recombinant vesicular stomatitis viruses (rVSVs), carrying a genetic sequence of filoviral glycoprotein (GP) and pseudotyped with correspondent GP. We showed that rVSV-EBOV-GP was 100% lethal for Ifnar1(-/-) mice after inoculation by multiple routes, and its active propagation was within 24 h post-infection. We performed dose-dependent lethality assessment in small groups to estimate median lethal doses for rVSV-EBOV-GP, rVSV-SUDV-GP, rVSV-BDBV-GP, rVSV-MARV-GP in Ifnar1-knockout mice and showed high viral load in liver and immune cell reservoirs. The developed models contribute to safe and effective research of filoviral vaccines and therapeutic antibodies under BSL-2 conditions.

  • Open Access

    Immunogenicity and Protectivity of Sputnik V Vaccine in hACE2-Transgenic Mice against Homologous and Heterologous SARS-CoV-2 Lineages Including Far-Distanced Omicron BA.5

    by Inna V. Dolzhikova, Amir I. Tukhvatulin, Daria M. Grousova, Ilya D. Zorkov, Marina E. Komyakova, Anna A. Ilyukhina, Anna V. Kovyrshina, Artem Y. Shelkov, Andrey G. Botikov, Ekaterina G. Samokhvalova, et al.

    Background: The SARS-CoV-2 virus continuously acquires mutations, leading to the emergence of new variants. Notably, the effectiveness of global vaccination efforts has significantly declined with the rise and spread of the B.1.1.529 (Omicron) variant. Methods: The study used virological, immunological and histological research methods, as well as methods of working with laboratory animals. In this study, we evaluated the Gam-COVID-Vac (Sputnik V), an adenoviral vaccine developed by the N.F. Gamaleya National Research Center for Epidemiology and Microbiology, and conducted experiments on hemizygous K18-ACE2-transgenic F1 mice. The variants studied included B.1.1.1, B.1.1.7, B.1.351, B.1.1.28/P.1, B.1.617.2, and B.1.1.529 BA.5. Results: Our findings demonstrate that the Sputnik V vaccine elicits a robust humoral and cellular immune response, effectively protecting vaccinated animals from challenges posed by various SARS-CoV-2 variants. However, we observed a notable reduction in vaccine efficacy against the B.1.1.529 (Omicron BA.5) variant. Conclusions: Our results indicate that ongoing monitoring of emerging mutations is crucial to assess vaccine efficacy against new SARS-CoV-2 variants to identify those with pandemic potential. If protective efficacy declines, it will be imperative to develop new vaccines tailored to current variants of the virus.


  • Open Access

    Lethality of West Nile virus strains in a mouse model

    by Andrei E. Siniavin, Inna V. Dolzhikova, Andrei A. Pochtovyi, Dmitry A. Reshetnikov, Vladimir A. Gushchin

    West Nile fever (WNF) is a viral infection caused by West Nile virus (WNV), a flavivirus of the Flaviviridae family. Virus circulates between mosquitoes and wild birds, but can infect other species, including humans. The first cases of West Nile fever were reported in Africa in the 1930s. Currently, WNV has a wide geographic range, which includes countries in Europe, Asia, Africa, Australia, and North and South America, where it periodically causes WNF outbreaks. The disease in human occurs with the development of fever, and in some cases ending up severe neurological complications. Studies of the virus in animal models demonstrate that virulence varies depending on the host species, the genotype of the virus, and the presence of substitutions in key viral proteins, even within the same genotype. These studies highlight the need for comparative studies of different WNV strains to evaluate the impact of amino acid substitutions on WNV pathogenesis. Analysis of key mutations and substitutions will allow the development of a safe and effective vaccine for the prevention of WNF.


  • Open Access

    Growth characteristics of human bone marrow mesenchymal stromal cells at cultivation on synthetic polyelectrolyte nanofilms in vitro

    by Lyudmila M. Mezhevikina, Dmitriy A. Reshetnikov, Maria G. Fomkina, Nurbol O. Appazov, Saltanat Zh. Ibadullayeva, Evgeniy E. Fesenko